IBI Cancer Research Results

IBI, Intestinal Barrier Integrity: Click to Expand ⟱
Source:
Type:

Intestinal Barrier Integrity (IBI) refers to the functional integrity of the gut mucosal barrier, including epithelial tight junctions, mucus protection, antimicrobial defenses, and control of luminal antigen and microbial translocation. Loss of intestinal barrier integrity increases permeability, promotes endotoxin and cytokine-driven inflammation, and can sustain tumor-supportive signaling through NF-κB, STAT3, oxidative stress, and immune dysregulation. In IBD, barrier disruption is a core pathogenic feature that amplifies chronic mucosal inflammation and tissue injury. In cancer, especially colorectal cancer, persistent barrier dysfunction may contribute to initiation, progression, and a pro-inflammatory microenvironment, although in some treatment contexts increased permeability can also alter drug exposure or immune interactions. Agents that improve intestinal barrier integrity may be relevant in IBD-associated carcinogenesis and in reducing inflammation-linked tumor promotion.

Related terms/synonyms: gut barrier, epithelial barrier, mucosal barrier, intestinal permeability, leaky gut.
Scientific Papers found: Click to Expand⟱
5932- CAR,    Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome
- in-vivo, IBD, NA - in-vivo, Park, NA
*GutMicro↑, Carvacrol can regulate the gut microbiota. bundance of specific microbiota, such as Lactobacillus, Escherichia coli/Shigella, and Lachnoclostridium.
Risk↓, Carvacrol inhibits the development of colitis-associated colorectal cancer.
*Inflam↓, nti-inflammatory and antioxidant traits,
*antiOx↓,
*ZO-1↑, carvacrol significantly restored colonic length (p < 0.01) and re-established key tight junction proteins like ZO-1.
*iNOS↓, downregulated mRNA levels of inflammatory mediators such as iNOS and IL-6.
*IL6↓,
*NO↓, carvacrol has been shown to suppress nitric oxide and prostaglandin E2 production
*PGE2↓,
*memory↑, carvacrol improves memory deficits in Parkinson’s disease models
*TLR4↓, anti-inflammatory effects of carvacrol by inhibiting the TLR4/NF-κB signaling pathway
*NF-kB↓,
*IBI↑, Carvacrol improves intestinal barrier function
*CLDN3↑, expression levels of ZO-1, Claudin3, Claudin1, Occludin, and Mucin were significantly increased in the carvacrol group compared to the DSS group
*CLDN1↑,
*MUC1↑,
*OCLN↑,
*iNOS↑, carvacrol significantly inhibited the mRNA expression levels of iNOS, COX-2, Interferon-γ, IL-1β, and IL-6 in the intestinal tracts of colitis mice
*COX2↓,
*IFN-γ↓,
IL1β↓,
ADAM10?,

6023- CGA,    Pharmacological advances of the chlorogenic acids family: current insights and future research directions
- Review, AD, NA - Review, Park, NA - Review, IBD, NA
*Aβ↓, chlorogenic acid can reduce Aβ plaques in Alzheimer’s disease model mice by 37%, indicating its neuroprotective potential.
*neuroP↑,
*cardioP↑, Similarly, CGAs offer protection to the cardiovascular system, gastrointestinal tract, kidneys, and liver, while additionally preventing metabolic syndrome and displaying anticancer and antimicrobial capabilities.
*GastroP↑,
*RenoP↑,
*hepatoP↑,
*Obesity↓,
*Bacteria↓,
*BioAv↑, hydroxycinnamoyl-CoA quinate hydroxycinnamoyl transferase, HQT in tomatoes significantly enhances CGA accumulation without significantly altering the levels of other soluble phenolic botanical drugs.
*BioAv↑, Mechanistic studies have shown that dietary fats (such as soybean oil and coconut oil) can significantly enhance the permeability of CGA in the Caco-2 monolayer by increasing cell membrane fluidity
*BioAv↑, Following oral administration of CGA, the acidic environment in the stomach helps maintain the structural stability of CGA, with approximately one-third of the dose entering the blood system through passive diffusion in the small intestine, while the
*ROS↓, CGA pretreatment markedly diminished ROS caused by PD toxins
*GutMicro↑, CGA works with the gut microbiota and its metabolites to alleviate post-infectious irritable bowel syndrome (PI-IBS)
*IBI↑, CGA increases intestinal damage repair, decreases MCT-1 and TFF-3 expression, and suppresses NF-κB expression
*MCT1↓,
*NF-kB↓,
*DNMT1↓, Liver Cancer, DNMT1 protein expression↓

5934- TV,    Protective Effects of Natural Antioxidants on Inflammatory Bowel Disease: Thymol and Its Pharmacological Properties
- Review, Var, NA
*Inflam↓, anti-inflammation, anti-oxidation, anti-bacteria, anti-fungal, and anti-tumor potential
*antiOx↑,
*Bacteria↓,
AntiTum↑,
*toxicity∅, A high dose of thymol up to 500 mg/kg diet has been shown to have no toxicity
*IBI↑, thymol improves intestinal integrity and alleviates intestinal injury via the regulation of the immune response and oxidation-reduction homeostasis
*ZO-1↑, increasing the expression of the tight junction protein zonula occludens-1 (ZO-1) and occludins
*OCLN↑,
*COX1↑, up-regulates cyclooxygenase-1 (COX1) activity
*TLR4↓, thymol inhibits TLR4 expression and then inhibits the activation of NF-κB signaling, which reduces the production of inflammatory cytokines, such as TNF-α and IL-1β [58,59]
*NF-kB↓,
*TNF-α↓,
*IL1β↓,
*TAC↑, Thymol Improves Anti-Oxidant Capacity in IBD
*NRF2↑, Studies have indicated that thymol activates Nrf2 signaling in different tissues
*GutMicro↑, Thymol Changes Gut Microbes and Prevents Pathogen Infection. thymol also promoted the colonization of beneficial bacteria, such as Clostridium, Lactobacillus, and Bacteroides, to improve gut health


Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,  

Synaptic & Neurotransmission ⓘ

ADAM10?, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   Risk↓, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   NRF2↑, 1,   ROS↓, 1,   TAC↑, 1,  

Cell Death ⓘ

iNOS↓, 1,   iNOS↑, 1,   MCT1↓, 1,  

DNA Damage & Repair ⓘ

DNMT1↓, 1,  

Migration ⓘ

CLDN1↑, 1,   MUC1↑, 1,   ZO-1↑, 2,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Barriers & Transport ⓘ

CLDN3↑, 1,   GastroP↑, 1,   IBI↑, 3,   OCLN↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX1↑, 1,   COX2↓, 1,   IFN-γ↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 3,   PGE2↓, 1,   TLR4↓, 2,   TNF-α↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 3,  

Clinical Biomarkers ⓘ

GutMicro↑, 3,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 1,   Obesity↓, 1,   RenoP↑, 1,   toxicity∅, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 2,  
Total Targets: 39

Scientific Paper Hit Count for: IBI, Intestinal Barrier Integrity
1 Carvacrol
1 Chlorogenic acid
1 Thymol-Thymus vulgaris
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1462  State#:%  Dir#:2
  wNotes=on  sortOrder:rid,rpid

 

Home Page